New study paves way for future treatments in rare brain disorder
NCT ID NCT06018519
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at people with creatine transporter deficiency, a rare genetic condition that causes intellectual disability, seizures, and movement problems. Researchers want to find the best tests to measure symptoms, since many standard tests are too hard for these patients. The goal is to prepare for future clinical trials of new treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 197 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2023
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
2 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Male CTD patients (n=24) * Male CTD patients having a confirmed mutation in the SLC6A8 gene, * Aged \> 5 to \< 35 years * Whose maternal language is French, * Having signed the informed consent and/or for whom parents/legal guardian have signed the informed consent, * Affiliated to national Health Insurance system or parents/legal guardian affiliated to national health insurance system. Female CTD patients (n=15) * Female CTD patients having a confirmed mutation in the SLC6A8 gene, * Aged \> 5 to \< 60 years, * Whose maternal language is French, * Having signed the informed consent and/or for whom parents/legal guardian have signed the informed consent. * Affiliated to national Health Insurance system (sécurité sociale) or parents/legal guardian affiliated to national health insurance system Sex- and chronological age-matched controls (n=24) * Male * Aged \> 5 to \< 35 years * Whose maternal language is French, * Having signed the informed consent and/or for whom parents/legal guardian have signed the informed consent, * Affiliated to national health insurance system or parents/legal guardian affiliated to national health insurance system. Sex- and chronological age-matched female controls (n=15) * female, * Aged \> 5 to \< 60 years, * Whose maternal language is French, * Having signed the informed consent and/or for whom parents/legal guardian have signed the informed consent * Affiliated to national Health Insurance system (sécurité sociale) or parents/legal guardian affiliated to national health insurance system Sex- and mental age-matched controls (n=39) * Male and female * Aged \> 2 to \< 8 years * Whose maternal language is French, * For whom parents/legal guardian have signed the informed consent, * Affiliated to national health insurance system or parents/legal guardian affiliated to national health insurance system. Typically developed children (n=80) * Male and female * Aged \> 2 to \< 8 years * Whose maternal language is French, * For whom parents/legal guardian have signed the informed consent, * Affiliated to national health insurance system or parents/legal guardian affiliated to national health insurance system. Sex- and chronological age-matched controls and Sex- and mental age-matched controls, aged \< 8 years, could also be included in the Typically developed children group, as the data from the Typically developed children are only necessary to complete the developmental trajectory of the new tasks. Non-inclusion Criteria: CTD patients (n=39): * Having a contraindication to the MRI examination (people using a pacemaker or an insulin pump, people wearing a metal prosthesis or an intracerebral clip, and claustrophobic subjects), * Refusal of the subject and/or the subject's parents to be informed of possible abnormalities detected by MRI, * Refusal of the subject and/or the subject's parents/legal guardian to be informed of possible abnormalities detected during the cardiac assessment. Sex- and chronological age-matched controls (n=39) * History of neurological or psychiatric disorder, * Repetition of a grade, * Learning disability requiring rehabilitation (speech therapy, psychomotor or oculomotor therapy), * For participants agreeing on performing the MRI examination, having a contraindication to the MRI examination (use of a pacemaker or an insulin pump, people wearing a metal prosthesis or an intracerebral clip, and claustrophobic subjects) and refusal of the subject and/or the subject's parents/legal guardian to be informed of possible abnormalities detected by MRI. Sex- and mental age-matched controls (n=39) * History of neurological or psychiatric disorder, * Repetition of a grade, * Learning disability requiring rehabilitation (speech therapy, psychomotor or oculomotor therapy). Typically developed children (n=80) * History of neurological or psychiatric disorder, * Repetition of a grade, * Learning disability requiring rehabilitation (speech therapy, psychomotor or oculomotor therapy).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Creatine transporter defect are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Woman, mother and child hospital, Hospices Civils de Lyon
RECRUITINGBron, 69500, France